Cerulean

Cerulean, a biotech with its own platform for creating nanoparticle-drug conjugates (NDCs) designed to selectively attack tumours, has made changes to its Board of Directors.

The company has appointed David Parkinson to its Board, and made him part of the firm’s Clinical Advisory Committee, also made up of Susan Kelley and Paul Friedman, all doctors.

Friedman this week assumed the role of Executive Chairman of Cerulean. He described Parkinson as having “outstanding experience​” in oncology R&D, including leadership roles at large pharmaceutical and biotechnology companies and oversight of a major branch of the National Cancer Institute.

Parkinson previously served as President and CEO of Nodality, a company focused on the biological characterization of signalling pathways in patients with malignancies. He has also been Senior VP of Oncology R&D at Biogen Idec, VP of Oncology Development at Amgen, and VP of  Global Clinical Oncology Development at Novartis.